Inside Stocks
Universe/Pharmaceutical Preparations/AMPH

Amphastar Pharmaceuticals, Inc.

AMPH · US · USD
Watchlist and comparison: planned
Market value1.29 bn USD
Industry per SECPharmaceutical Preparations
Price as of12 Oct 2026
Last financial year2025
Latest filing10-Q, 6 Aug 2026
Method version2.7.0
Years in the base11
Company quality, four grades from 0 to 5
Balance sheet5
Profitability3
Cash flow4
Growth5
Total points17 of 20
Share valuation, scored separately
Position in the rangebelow

The key figures

free to read

All values from audited annual reports filed with the US regulator SEC. No value is estimated, none smoothed.

GradePointsBasis
Balance sheet5/5Net debt to operating income 2.0× · Current ratio 4.0
How this grade is built
Net debt to operating income2.0×4/51: ≤ 5.0×2: ≤ 4.0×3: ≤ 3.0×4: ≤ 2.0×5: ≤ 1.0×Next step: at most 1.0× for grade 5
Current ratio4.05/51: ≥ 0.82: ≥ 1.03: ≥ 1.34: ≥ 1.85: ≥ 2.5
Mean 4 + 5 / 2 = 4.50, rounded 5
Profitability3/5Operating margin 19.5% · Return on equity 12.4%
How this grade is built
Operating margin19.5%3/51: ≥ 0.0%2: ≥ 5.0%3: ≥ 12.0%4: ≥ 20.0%5: ≥ 30.0%Next step: at least 20.0% for grade 4
Return on equity12.4%3/51: ≥ 0.0%2: ≥ 5.0%3: ≥ 10.0%4: ≥ 18.0%5: ≥ 25.0%Next step: at least 18.0% for grade 4
Mean 3 + 3 / 2 = 3.00, rounded 3
Cash flow4/5Free cash flow to revenue 16.8% · Profit covered by cash flow 1.2× · Free cash flow positive 5 of 5 years
How this grade is built
Free cash flow to revenue16.8%3/51: ≥ 0.0%2: ≥ 5.0%3: ≥ 10.0%4: ≥ 18.0%5: ≥ 25.0%Next step: at least 18.0% for grade 4
Profit covered by cash flow1.2×5/51: ≥ 0.4×2: ≥ 0.6×3: ≥ 0.8×4: ≥ 1.0×5: ≥ 1.2×
Free cash flow positive5 of 5 years5/51: 1 of 52: 2 of 53: 3 of 54: 4 of 55: 5 of 5
Mean 3 + 5 + 5 / 3 = 4.33, rounded 4
Growth5/5Revenue growth per year 15.5% · Operating income per year 66.6%
How this grade is built
Revenue growth per year15.5%4/51: ≥ 0.0%2: ≥ 3.0%3: ≥ 8.0%4: ≥ 15.0%5: ≥ 25.0%Next step: at least 25.0% for grade 5
Operating income per year66.6%5/51: ≥ 0.0%2: ≥ 3.0%3: ≥ 8.0%4: ≥ 15.0%5: ≥ 25.0%
Mean 4 + 5 / 2 = 4.50, rounded 5

Each grade is the rounded mean of two or three key figures, each placed on a five-step scale. Open the derivation under a grade to see, for every figure, the measured value, the step it reached and what the next step would have required.

The valuation range

free to read

The range comes from this company's own history, not from a comparison with others. Price today 26.76 EUR, range 32.97 to 41.65 EUR. The price sits below the lower edge of its own valuation range. The middle of the range sits 39.4% above today's price. Reliability: robust, from 5 methods.

MethodTodaySeriesYears
Price to earnings13,22019–20256
Price to revenue1,82016–202510
Price to book value1,62016–202510
Enterprise value to revenue2,32016–202510
Enterprise value to operating profit11,62021–20255

Open each method to see the arithmetic year by year.

Price to earnings
YearPriceBasisMultiple
201919,290,9819,7
202123,291,2518,6
202228,021,7416,1
202361,852,6023,8
202437,133,0612,1
202526,782,0313,2
heute26,762,0313,2
Price to revenue
YearPriceBasisMultiple
201618,425,373,4
201719,244,973,9
201819,906,353,1
201919,296,463,0
202020,117,122,8
202123,298,792,6
202228,029,522,9
202361,8512,165,1
202437,1314,062,6
202526,7814,931,8
heute26,7614,931,8
Price to book value
YearPriceBasisMultiple
201618,426,932,7
201719,246,902,8
201819,907,172,8
201919,297,642,5
202020,118,192,5
202123,298,952,6
202228,0210,082,8
202361,8512,065,1
202437,1314,072,6
202526,7816,361,6
heute26,7616,361,6
Enterprise value to revenue
YearPriceBasisMultiple
201618,42255,163,3
201719,24240,183,8
201819,90294,673,0
201919,29322,362,9
202020,11349,852,7
202123,29437,772,5
202228,02498,992,7
202361,85644,395,6
202437,13731,973,2
202526,78719,892,3
heute26,76719,892,3
Enterprise value to operating profit
YearPriceBasisMultiple
202123,2969,8915,8
202228,02107,5012,7
202361,85196,9918,4
202437,13205,4211,3
202526,78140,4011,6
heute26,76140,4011,6

Price divided by basis gives the multiple. Every row can be recomputed; if a row does not add up, this page is not built at all.

Within the sector

free to read

Rank 9 of 152 in the industry. Median of total points in this industry: 10.0 of 20, across 152 graded companies. The grades are absolute and are not normalised to the sector: in a weak industry a weak grade stays weak.

one place above
Alnylam Pharmaceuticals, Inc.
ALNY
17/20
one place below
ANI Pharmaceuticals Inc.
ANIP
17/20

The neighbours follow from the ranking alone, not from a judgement. More total points does not mean a company is the better investment, only that more quality rules are met. It says nothing about the price.

The series of figures

free to read

Every figure comes from the annual report of that year and has not been revised afterwards. Amounts in USD.

Swipe sideways for all columns.

YearRevenueOperating profitFree cash flowEarnings per shareSharesNet debt
2015251.52 m-6.90 m-5.32 m-0.0644.96 m-25.78 m
2016255.16 m15.38 m17.18 m0.2147.50 m-36.85 m
2017240.18 m-1.27 m4.11 m0.0848.37 m-22.50 m
2018294.67 m-8.62 m-8.62 m-0.1246.40 m-40.07 m
2019322.36 m-39.00 k207.00 k0.9849.91 m-39.04 m
2020349.85 m10.95 m23.41 m0.0349.12 m-59.70 m
2021437.77 m69.89 m70.54 m1.2549.78 m-58.49 m
2022498.99 m107.50 m65.15 m1.7452.43 m-99.12 m
2023644.39 m196.99 m145.34 m2.6053.00 m346.37 m
2024731.97 m205.42 m172.34 m3.0652.06 m391.89 m
2025719.89 m140.40 m121.23 m2.0348.22 m336.89 m

How durable the advantage is

free to read

4 of 10 points, measured over 10 years (2016 to 2025). Classification: weak.

FeaturePointsBasis
Return on capital, level0/3The company earns on average 6.1% of its assets per year as operating profit, measured over 10 years. Comparable companies are around 10%.
Return on capital, consistency1/34 of 10 years above 10%. Consistency is the real evidence, because anyone has one good year.
Pricing power2/2Gross margin averaging 43%, trending +11.2 percentage points from the first third to the last. A margin that holds for a decade is pricing power. One that melts away is competition.
Stability in a downturn1/2Operating margin averaging 11%. Tested in 2020 and 2022: 2020 3%, 2022 22%. Holding counts from two thirds of the company's own average.

What is measured is the trace of a moat: a durably high return on capital and margins that survive a downturn. The causes (switching costs, network effects, brand, licences, economies of scale) appear in no filing and are not claimed here.

Next figures

Expected on 5 Nov 2026 (estimated from the rhythm of earlier filings, ± 3 days). Grades can change after a report; the page is then rebuilt.

Required disclosures for this analysis

Produced byFlorian Maier
Completed on14.10.2026 03:58
Price as of12 Oct 2026
Latest filing10-Q, 6 Aug 2026
Method version2.7.0
Time horizonThe grades describe a state that can change with every annual report, so roughly quarterly. The historical analysis is computed over 36 months.
Own positionNot disclosed individually, see the risk notice.
Earlier analysesThe list of all analyses of this company from the past twelve months will appear once twelve months of analyses exist. This run is the start of the series.

This is not investment advice. Limits of the method, assumptions and conflicts of interest: risk notice.